Main CRO Parexel has signed up with bioanalytics firm Synexa Life Sciences and blood drawing specialist Drawbridge Well being for a “extra streamlined resolution for blood pattern assortment and serology testing.”
Below the new pact, financials of which weren’t made public, Parexel will provide Synexa Life Sciences’ serology check, which may assess whether or not you might have or had a virus resembling SARS-CoV-02, and Drawbridge Well being’s OneDraw distant blood assortment gadget to prospects as a part of the corporate’s greater than 125 ongoing COVID-19 trials and initiatives.
“Our strategic collaboration with Synexa and Drawbridge Well being will allow Parexel to considerably enhance the scientific trial expertise for our sufferers collaborating in pivotal COVID-19 scientific trials,” stated Sy Pretorius, M.D., Parexel govt vice chairman, chief medical officer and chief scientific officer.
“Distant pattern assortment for serology testing removes the assorted obstacles of in-person assortment and improves accessibility for sufferers in want.”
Parexel stated this comes at a time when there may be “an pressing want” for correct serology testing that additionally reduces the chance of publicity to COVID-19. Its tripartite pact ought to go a good distance towards serving to this, it believes.
RELATED: Parexel pens Datavant tech deal for trial workflows
“We’re thrilled to proceed our partnership with Parexel and additional make the most of the corporate’s platform and companies to scale our serology testing,” added Paul O’Riordan, CEO of Synexa Life Sciences. “The OneDraw Blood Assortment Machine has labored very properly with our panel of COVID-19 antibody assays, opening up the chance for large-scale distributed sampling in scientific trial or sero-prevalence research.”
“Offering options for antibody testing in help of scientific trials and ongoing sero-surveillance research for COVID-19 is a well timed and essential step for Drawbridge,” stated Lee McCracken, CEO of Drawbridge Well being.
